STOCK TITAN

Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Masaru Matsuda reported Rule 144 sale notices for Arcutis Biotherapeutics common stock. The filing lists sales of 40,638, 3,325 and 1,675 shares in the past three months, and separately lists restricted stock vesting of 6,746, 3,325 and 1,987 shares on the dates shown.

The broker listed is Merrill Lynch and the security trades on NASDAQ. The filing records transaction dates including 02/02/2026, 02/27/2026 and 12/01/2025.

Positive

  • None.

Negative

  • None.

Insights

Rule 144 sale notices from a single reporting person are routine disclosures of secondary market activity.

The excerpt lists three sale entries by Masaru Matsuda totaling the individual amounts 40,638, 3,325 and 1,675 shares with transaction dates in 12/01/2025, 02/02/2026 and 02/27/2026

Separately, the filing shows restricted stock vesting events of 6,746, 3,325 and 1,987 shares on their listed dates; timing and disposition of vested shares depend on the holder's decisions and are not detailed here.

Broker and trading venue are identified; the filing documents executed sales rather than an issuer offering.

The broker is listed as Merrill Lynch and the security is on NASDAQ, indicating standard market channels for the disclosed transactions. The entries are transactional records, not an issuance or shelf registration.

Cash‑flow treatment to the issuer is not included in the excerpt; subsequent filings would state any additional context if required.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What Rule 144 sales did Masaru Matsuda report for ARQT?

Masaru Matsuda reported sales of 40,638, 3,325 and 1,675 ARQT shares. The filing lists those three sale transactions with dates including 02/02/2026 and 02/27/2026.

Does the Form 144 show restricted stock vesting for ARQT?

Yes. The filing lists restricted stock vesting of 6,746, 3,325 and 1,987 common shares on the specific vesting dates shown in the excerpt, tied to the holder rather than an issuer sale.

Which broker and exchange are shown in the Form 144 for ARQT?

The broker is listed as Merrill Lynch with an address on Lyra Drive, Columbus, OH, and the security is identified as trading on NASDAQ in the excerpt provided.

Are proceeds to the company reported in this Form 144 for ARQT?

No. The excerpt documents secondary sales and vesting events; it does not state that any proceeds were received by the issuer or provide use‑of‑proceeds information in the provided text.

What dates are tied to the reported transactions in the ARQT filing?

Transaction and vesting dates shown include 12/01/2025, 02/02/2026, 02/27/2026, and vesting entries on 03/01/2026 and 03/02/2025 as listed in the excerpt.
Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

ARQT Rankings

ARQT Latest News

ARQT Latest SEC Filings

ARQT Stock Data

3.03B
110.26M
Biotechnology
Pharmaceutical Preparations
Link
United States
WESTLAKE VILLAGE